Literature DB >> 2611322

Monitoring accumulating data in a clinical trial.

D A Berry1.   

Abstract

A clinical trial is monitored for efficacy or safety; the variable of interest is death or a similarly serious event. The probability that one therapy has a greater mortality rate than the other is calculated ad libitum during the trial. Adjustments are made for differing patients' prognoses and for survival times.

Entities:  

Mesh：

Year:  1989        PMID： 2611322

Source DB:  PubMed          Journal:  Biometrics        ISSN： 0006-341X            Impact factor:   2.571


  9 in total

1.  Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemia.

Authors:  Susan O'Brien; David A Rizzieri; Norbert Vey; Farhad Ravandi; Utz O Krug; Mikkael A Sekeres; Mike Dennis; Adriano Venditti; Donald A Berry; Tove Flem Jacobsen; Karin Staudacher; Trygve Bergeland; Francis J Giles
Journal:  Br J Haematol       Date:  2012-06-15       Impact factor: 6.998

2.  A new statistical method for dose-finding based on efficacy and toxicity in early phase clinical trials.

Authors:  P F Thall; E H Estey; H G Sung
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

3.  A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome.

Authors:  Stefan Faderl; Guillermo Garcia-Manero; Elias Jabbour; Farhad Ravandi; Gautam Borthakur; Zeev Estrov; Varsha Gandhi; Anna L Byrd; Monica Kwari; Jorge Cortes; Hagop M Kantarjian
Journal:  Cancer       Date:  2011-07-12       Impact factor: 6.860

4.  Estimating design operating characteristics in Bayesian adaptive clinical trials.

Authors:  Shirin Golchi
Journal:  Can J Stat       Date:  2022-04-15       Impact factor: 0.758

5.  The utility of Bayesian predictive probabilities for interim monitoring of clinical trials.

Authors:  Benjamin R Saville; Jason T Connor; Gregory D Ayers; JoAnn Alvarez
Journal:  Clin Trials       Date:  2014-05-28       Impact factor: 2.486

6.  Adaptive designs in clinical trials.

Authors:  Suresh Bowalekar
Journal:  Perspect Clin Res       Date:  2011-01

7.  Interim analyses and stopping rules in cancer clinical trials.

Authors:  J Whitehead
Journal:  Br J Cancer       Date:  1993-12       Impact factor: 7.640

Review 8.  Statistical methods for the analysis of adverse event data in randomised controlled trials: a scoping review and taxonomy.

Authors:  Rachel Phillips; Odile Sauzet; Victoria Cornelius
Journal:  BMC Med Res Methodol       Date:  2020-11-30       Impact factor: 4.615

Review 9.  Application of Bayesian methods to accelerate rare disease drug development: scopes and hurdles.

Authors:  Kelley M Kidwell; Satrajit Roychoudhury; Barbara Wendelberger; John Scott; Tara Moroz; Shaoming Yin; Madhurima Majumder; John Zhong; Raymond A Huml; Veronica Miller
Journal:  Orphanet J Rare Dis       Date:  2022-05-07       Impact factor: 4.303
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.